INDIANAPOLIS, Oct 8, 2025 – Telehealth company HealthTap joined Eli Lilly’s (LLY.N) digital healthcare platform LillyDirect to offer virtual diabetes management services, expanding access to primary care-driven treatment options.

The partnership positions Lilly to capture more diabetes patient touchpoints beyond drug sales, potentially boosting long-term revenue streams as the company faces growing competition in the diabetes treatment market.

  • HealthTap becomes first independent telehealth provider on LillyDirect platform
  • Services target type 1 and type 2 diabetes patients
  • Partnership expands Lilly’s digital healthcare ecosystem reach

Market reaction & context

HealthTap will serve as the first independent telehealth primary care provider on LillyDirect, offering virtual consultations for patients with type 1 and type 2 diabetes 1. The move comes as pharmaceutical companies increasingly seek to build direct relationships with patients through digital platforms, moving beyond traditional drug distribution models.

Lilly’s diabetes franchise generated approximately 7.5 billion in revenue in 2024, making the therapeutic area a key growth driver for the Indianapolis-based pharmaceutical giant.

Detailed analysis

The partnership allows HealthTap’s clinicians to provide comprehensive diabetes care including medication management, lab review, and preventive care tailored to individual patient conditions 3. This integration represents a strategic expansion of Lilly’s LillyDirect platform, which launched to provide patients direct access to select Lilly medications and now extends into broader healthcare services.

HealthTap’s addition to the platform could help Lilly compete more effectively against integrated healthcare providers and other pharmaceutical companies building similar digital ecosystems. The collaboration also addresses growing demand for telehealth services, which surged during the pandemic and have maintained elevated usage levels.

Management perspective

HealthTap CEO Sean Mehra expressed optimism about the collaboration’s potential impact on diabetes care accessibility. The partnership aims to bridge gaps in traditional healthcare delivery by providing patients comprehensive virtual care options through a pharmaceutical company’s digital platform.

“HealthTap believes Eli Lilly’s platform offers significant opportunities to expand diabetes care access,” the company said in announcing the partnership 3.

Strategic implications

The collaboration reflects broader industry trends toward vertical integration in healthcare, where pharmaceutical companies seek to control more of the patient care journey. For Lilly, the partnership could improve patient adherence to diabetes medications while generating additional revenue through healthcare services.

The move also positions both companies to benefit from the growing digital health market, which analysts project will continue expanding as patients increasingly seek convenient, technology-enabled care options.

Not investment advice. For informational purposes only.

References

1(Oct 8, 2025). “HealthTap joins Lilly’s online platform to offer diabetes management services”. Reuters. Retrieved Oct 8, 2025.

2(Oct 8, 2025). “HealthTap joins Lilly’s online platform to offer diabetes management services”. Yahoo News. Retrieved Oct 8, 2025.

3(Oct 8, 2025). “HealthTap joins LillyDirect, bringing primary care to pharma site”. Fierce Healthcare. Retrieved Oct 8, 2025.

4(Oct 8, 2025). “HealthTap Expands Access to Primary Care-Driven Diabetes Treatment Through LillyDirect”. Business Wire. Retrieved Oct 8, 2025.

5(Oct 8, 2025). “HealthTap Expands Access to Primary Care-Driven Diabetes”. Yahoo Finance. Retrieved Oct 8, 2025.